XClose

Institute for Global Health

Home
Menu

Pharmacokinetics-Pharmacodynamics Group

We aim to characterise the relationship between drug concentrations and effects. One uses these so called pharmacokinetic-pharmacodynamic relationships to select and optimise dosing regimens.

Research activities

Our research portfolio, that aims to improve our understanding of mechanisms underlying responses to medicines, currently has three research themes:

  1. There are currently no good biomarkers that can predict the tuberculosis treatment outcome during the first eight weeks of treatment. Clinical trials investigating novel anti-tuberculosis drugs and standard of care are consequently very long given that treatment of tuberculosis currently lasts for six months. To that end we have designed and been running observational pharmacokinetic-pharmacodynamic cohorts in the UK and abroad to investigate in-vivo candidate biomarkers for cure during treatment of active tuberculosis. (link1 and link2).
  2. Biomarkers for bacterial sub-populations that are able to survive antimicrobial combination treatment are crucial for rational based antimicrobial combination therapy selection. However, biomarkers are lacking, limiting our ability to investigate responses to anti-mycobacterial drug-drug combinations. To that purpose we have setup a series of in-vitro experiments at the UCL Centre for Clinical Microbiology to investigate mechanisms underlying emergence of resistance. (link3 & link4)
  3. A single big pharmacokinetic-pharmacodynamic data source is currently lacking, which prevents taking full benefit from machine learning within the space of pharmacokinetic-pharmacodynamic modelling methods. We therefore started PKPDai, an initiative that brings together quantitative pharmacometric knowledge into a single open-source platform, thereby making it amenable to the application of machine learning. (link5 & link6)

Research disciplines, methods & techniques

Pharmacology

Microbiology

In-vivo pharmacokinetic-pharmacodynamic studies

In-vitro microbiology

In-vitro pharmacology

In-vitro Hollow Fibre Infection model (HFIM)

Population Pharmacokinetic-Pharmacodynamic modelling (pop PKPD)

Natural Language Processing (NLP)


Software and Databases

PKPDAI toolkit 

Pump settings for in-vitro hollow-fibre experiments

PharmPow


Group members

Frank Kloprogge
Sir Henry Dale Fellow

Constantino Gonzalez-Bridger 
Research Assistant

Shalom Ajagbe
Research Assistant

Zhonghui Huang 
PhD Student

Ali Issa 
PhD Student

Dhyan Kusama Ayuningtyas
PhD Student

Jegak Seo
PhD Student

Former group members

Asma Ashraf, CRN Research Nurse

Caroline Ramsey, CRN Research Nurse

Vanessa Hack, CRN Research Project Manager

Arundhati MaitraResearch Fellow in antimicrobial pharmacodynamics

Zahra Sadouki, PhD Student

Marie Sjölin Wijk, Visiting PhD student from University of Cape Town

Jelmer Raaijmakers, Visiting PhD student from Radboud Universiteit

Xavier Torres, Erasmus+ student

Anna Keszthelyi, Intern

Elin Dumont, LIDo rotation student

Isabelle Papandronicou, LIDo rotation student

Celeste Watson, Research Assistant